← All trials
NCT05847218
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2023
- Primary completion
- Mar 19, 2023
- Completion date
- Mar 19, 2023
- First posted
- May 6, 2023
- Last posted
- May 6, 2023
- Enrollment
- 64
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- RH NanopharmaceuticalsLead sponsor
- University of KarachiCollaborator
- University of KarachiOverall official - principal investigator
- University of KarachiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.